Stockholm3 has been evaluated in large clinical studies and in clinical practice. Clinical data from almost 80,000 men demonstrate that Stockholm3 finds 100 percent more aggressive prostate cancers and reduce unnecessary biopsies by 5o percent compared to current practice. Results have been published in The Lancet Oncology, Nature Reviews, Clinical Oncology and European Urology.

The cost effectiveness of prostate cancer screening using the Stockholm3 test. Karlsson et al, Plos One. 2020

Vinje et al. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system – the Stavanger experience. SJPHC. 2020

Bergman et al. Structured care for men who want to get tested for prostate cancer – findings from Capio Prostate Cancer Center. Läkartidningen. 2018

Grönberg et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol. 2018

Regional tillämpning prostatacancerdiagnostik. 2018

Eklund et al. The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50–69 yr Compared with Current Prostate Cancer Testing. Eur Urol Focus. 2016

Grönberg et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncology. 2015

Aly et al. Rapid increase in multidrug-Resistant Enteric Bacilli Blood Stream Infection After Prostate Biopsy—A 10-Year Population-Based Cohort Study. The Prostate. 2015

Nordstrom et al. Prostate-specific antigen (PSA) Testing Is Prevalent and Increasing in Stockholm County, Sweden, Despite No Recommendations for PSA Screening. Eur Urol. 2013